{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T13:07:04Z","timestamp":1792242424739,"version":"4.4.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T00:00:00Z","timestamp":1752883200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T00:00:00Z","timestamp":1752883200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100015303","name":"Otsuka Pharmaceutical Development and Commercialization","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015303","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013327","name":"H. Lundbeck A\/S","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013327","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s40263-025-01200-9","type":"journal-article","created":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T02:33:56Z","timestamp":1752892436000},"page":"1011-1023","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Safety and Tolerability of Brexpiprazole in Participants with Agitation Associated with Dementia due to Alzheimer\u2019s Disease: Pooled Analysis of Three Randomized Trials and an Extension Trial"],"prefix":"10.1007","volume":"39","author":[{"given":"Alpesh","family":"Shah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvin","family":"Estilo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela L","family":"Sheridan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwa","family":"Kalu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Slomkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanco","family":"Hefting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Hobart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saloni","family":"Behl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1905-1142","authenticated-orcid":false,"given":"Pedro","family":"Such","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malaak","family":"Brubaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George T","family":"Grossberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,19]]},"reference":[{"issue":"3","key":"1200_CR1","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1002\/gps.5030","volume":"34","author":"R Halpern","year":"2019","unstructured":"Halpern R, Seare J, Tong J, Hartry A, Olaoye A, Aigbogun MS. Using electronic health records to estimate the prevalence of agitation in Alzheimer disease\/dementia. Int J Geriatr Psychiatry. 2019;34(3):420\u201331. https:\/\/doi.org\/10.1002\/gps.5030.","journal-title":"Int J Geriatr Psychiatry"},{"issue":"12","key":"1200_CR2","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1002\/gps.5604","volume":"36","author":"H Fillit","year":"2021","unstructured":"Fillit H, Aigbogun MS, Gagnon-Sanschagrin P, Cloutier M, Davidson M, Serra E, et al. Impact of agitation in long-term care residents with dementia in the United States. Int J Geriatr Psychiatry. 2021;36(12):1959\u201369. https:\/\/doi.org\/10.1002\/gps.5604.","journal-title":"Int J Geriatr Psychiatry"},{"issue":"11","key":"1200_CR3","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1517\/14656566.2015.1059422","volume":"16","author":"IM Antonsdottir","year":"2015","unstructured":"Antonsdottir IM, Smith J, Keltz M, Porsteinsson AP. Advancements in the treatment of agitation in Alzheimer\u2019s disease. Expert Opin Pharmacother. 2015;16(11):1649\u201356. https:\/\/doi.org\/10.1517\/14656566.2015.1059422.","journal-title":"Expert Opin Pharmacother"},{"key":"1200_CR4","unstructured":"Cloak N, Schoo C, Al Khalili Y. Behavioral and psychological symptoms in dementia. 2024 [cited 2024 July 30]; Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK551552\/"},{"issue":"9","key":"1200_CR5","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1176\/appi.ajp.2012.11101529","volume":"169","author":"H Brodaty","year":"2012","unstructured":"Brodaty H, Arasaratnam C. Meta-analysis of nonpharmacological interventions for neuropsychiatric symptoms of dementia. Am J Psychiatry. 2012;169(9):946\u201353. https:\/\/doi.org\/10.1176\/appi.ajp.2012.11101529.","journal-title":"Am J Psychiatry"},{"key":"1200_CR6","unstructured":"Otsuka Pharmaceutical Co. Ltd. Rexulti\u00ae (brexpiprazole) tablets, for oral use. Prescribing information [United States]. 2024 [cited 2024 June 3]; Available from: https:\/\/www.otsuka-us.com\/media\/static\/Rexulti-PI.pdf"},{"key":"1200_CR7","unstructured":"Otsuka Pharmaceutical Co. Ltd. Rexulti\u00ae brexpiprazole tablets. Product monograph [Canada]. 2024 [cited 2024 June 3]; Available from: https:\/\/rexultimonograph.ca\/"},{"key":"1200_CR8","unstructured":"Otsuka Pharmaceutical Co. Ltd. Otsuka obtains additional indication for Rexulti\u00ae in Japan as an adjunctive treatment for agitation associated with dementia due to Alzheimer\u2019s disease. 2024 [cited 2024 November 5]; Available from: https:\/\/www.otsuka.co.jp\/en\/company\/newsreleases\/2024\/20240924_2.html"},{"issue":"4","key":"1200_CR9","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jagp.2019.09.009","volume":"28","author":"GT Grossberg","year":"2020","unstructured":"Grossberg GT, Kohegyi E, Mergel V, Josiassen MK, Meulien D, Hobart M, et al. Efficacy and safety of brexpiprazole for the treatment of agitation in Alzheimer\u2019s dementia: two 12-week, randomized, double-blind, placebo-controlled trials. Am J Geriatr Psychiatry. 2020;28(4):383\u2013400. https:\/\/doi.org\/10.1016\/j.jagp.2019.09.009.","journal-title":"Am J Geriatr Psychiatry"},{"issue":"12","key":"1200_CR10","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1001\/jamaneurol.2023.3810","volume":"80","author":"D Lee","year":"2023","unstructured":"Lee D, Slomkowski M, Hefting N, Chen D, Larsen KG, Kohegyi E, et al. Brexpiprazole for the treatment of agitation in Alzheimer dementia: a randomized clinical trial. JAMA Neurol. 2023;80(12):1307\u201316. https:\/\/doi.org\/10.1001\/jamaneurol.2023.3810.","journal-title":"JAMA Neurol"},{"issue":"2","key":"1200_CR11","doi-asserted-by":"publisher","first-page":"520","DOI":"10.3233\/JAD-240491","volume":"102","author":"S Behl","year":"2024","unstructured":"Behl S, Slomkowski M, Chen D, Chang D, Hefting N, Lee D, et al. Brexpiprazole for the treatment of agitation associated with dementia due to Alzheimer\u2019s disease: a 12-week, active-treatment, extension trial. J Alzheimers Dis. 2024;102(2):520\u20139. https:\/\/doi.org\/10.3233\/JAD-240491.","journal-title":"J Alzheimers Dis"},{"key":"1200_CR12","unstructured":"Cohen-Mansfield J. Instruction manual for the Cohen-Mansfield Agitation Inventory (CMAI). Rockville: The Research Institute of the Hebrew Home of Greater Washington; 1991."},{"issue":"3","key":"1200_CR13","doi-asserted-by":"publisher","first-page":"M77","DOI":"10.1093\/geronj\/44.3.m77","volume":"44","author":"J Cohen-Mansfield","year":"1989","unstructured":"Cohen-Mansfield J, Marx MS, Rosenthal AS. A description of agitation in a nursing home. J Gerontol. 1989;44(3):M77-84. https:\/\/doi.org\/10.1093\/geronj\/44.3.m77.","journal-title":"J Gerontol"},{"key":"1200_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-076268","volume":"385","author":"PLH Mok","year":"2024","unstructured":"Mok PLH, Carr MJ, Guthrie B, Morales DR, Sheikh A, Elliott RA, et al. Multiple adverse outcomes associated with antipsychotic use in people with dementia: population based matched cohort study. BMJ. 2024;385: e076268. https:\/\/doi.org\/10.1136\/bmj-2023-076268.","journal-title":"BMJ"},{"issue":"3","key":"1200_CR15","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.0828","volume":"2","author":"I Yunusa","year":"2019","unstructured":"Yunusa I, Alsumali A, Garba AE, Regestein QR, Eguale T. Assessment of reported comparative effectiveness and safety of atypical antipsychotics in the treatment of behavioral and psychological symptoms of dementia: a network meta-analysis. JAMA Netw Open. 2019;2(3): e190828. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.0828.","journal-title":"JAMA Netw Open"},{"issue":"3","key":"1200_CR16","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.3233\/jad-200127","volume":"77","author":"MS Aigbogun","year":"2020","unstructured":"Aigbogun MS, Cloutier M, Gauthier-Loiselle M, Guerin A, Ladouceur M, Baker RA, et al. Real-world treatment patterns and characteristics among patients with agitation and dementia in the United States: findings from a large, observational, retrospective chart review. J Alzheimers Dis. 2020;77(3):1181\u201394. https:\/\/doi.org\/10.3233\/jad-200127.","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"1200_CR17","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s40266-022-00992-5","volume":"40","author":"M Rogowska","year":"2023","unstructured":"Rogowska M, Thornton M, Creese B, Velayudhan L, Aarsland D, Ballard C, et al. Implications of adverse outcomes associated with antipsychotics in older patients with dementia: a 2011\u20132022 update. Drugs Aging. 2023;40(1):21\u201332. https:\/\/doi.org\/10.1007\/s40266-022-00992-5.","journal-title":"Drugs Aging"},{"key":"1200_CR18","unstructured":"U.S. Food and Drug Administration. FDA public health advisory: deaths with antipsychotics in elderly patients with behavioral disturbances. 2005 [cited 2023 October 24]; Available from: https:\/\/psychrights.org\/drugs\/FDAantipsychotics4elderlywarning.htm"},{"issue":"5","key":"1200_CR19","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1038\/sj.npp.1301492","volume":"33","author":"DV Jeste","year":"2008","unstructured":"Jeste DV, Blazer D, Casey D, Meeks T, Salzman C, Schneider L, et al. ACNP white paper: update on use of antipsychotic drugs in elderly persons with dementia. Neuropsychopharmacology. 2008;33(5):957\u201370. https:\/\/doi.org\/10.1038\/sj.npp.1301492.","journal-title":"Neuropsychopharmacology"},{"issue":"15","key":"1200_CR20","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1001\/jama.294.15.1934","volume":"294","author":"LS Schneider","year":"2005","unstructured":"Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294(15):1934\u201343. https:\/\/doi.org\/10.1001\/jama.294.15.1934.","journal-title":"JAMA"},{"issue":"3","key":"1200_CR21","doi-asserted-by":"publisher","first-page":"915","DOI":"10.3233\/jad-140579","volume":"42","author":"H Ma","year":"2014","unstructured":"Ma H, Huang Y, Cong Z, Wang Y, Jiang W, Gao S, et al. The efficacy and safety of atypical antipsychotics for the treatment of dementia: a meta-analysis of randomized placebo-controlled trials. J Alzheimers Dis. 2014;42(3):915\u201337. https:\/\/doi.org\/10.3233\/jad-140579.","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"1200_CR22","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1001\/jamainternmed.2014.6930","volume":"175","author":"LA Fraser","year":"2015","unstructured":"Fraser LA, Liu K, Naylor KL, Hwang YJ, Dixon SN, Shariff SZ, et al. Falls and fractures with atypical antipsychotic medication use: a population-based cohort study. JAMA Intern Med. 2015;175(3):450\u20132. https:\/\/doi.org\/10.1001\/jamainternmed.2014.6930.","journal-title":"JAMA Intern Med"},{"issue":"7","key":"1200_CR23","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1212\/wnl.34.7.939","volume":"34","author":"G McKhann","year":"1984","unstructured":"McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer\u2019s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer\u2019s Disease. Neurology. 1984;34(7):939\u201344. https:\/\/doi.org\/10.1212\/wnl.34.7.939.","journal-title":"Neurology"},{"issue":"3","key":"1200_CR24","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"MF Folstein","year":"1975","unstructured":"Folstein MF, Folstein SE, McHugh PR. \u201cMini-Mental State\u201d. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189\u201398. https:\/\/doi.org\/10.1016\/0022-3956(75)90026-6.","journal-title":"J Psychiatr Res"},{"issue":"12","key":"1200_CR25","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1212\/wnl.44.12.2308","volume":"44","author":"JL Cummings","year":"1994","unstructured":"Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44(12):2308\u201314. https:\/\/doi.org\/10.1212\/wnl.44.12.2308.","journal-title":"Neurology"},{"issue":"1","key":"1200_CR26","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1097\/00019442-200002000-00010","volume":"8","author":"S Wood","year":"2000","unstructured":"Wood S, Cummings JL, Hsu MA, Barclay T, Wheatley MV, Yarema KT, et al. The use of the Neuropsychiatric Inventory in nursing home residents. Characterization and measurement. Am J Geriatr Psychiatry. 2000;8(1):75\u201383. https:\/\/doi.org\/10.1097\/00019442-200002000-00010.","journal-title":"Am J Geriatr Psychiatry"},{"issue":"4","key":"1200_CR27","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1017\/S1041610222001041","volume":"36","author":"M Sano","year":"2024","unstructured":"Sano M, Cummings J, Auer S, Bergh S, Fischer CE, Gerritsen D, et al. Agitation in cognitive disorders: progress in the International Psychogeriatric Association consensus clinical and research definition. Int Psychogeriatr. 2024;36(4):238\u201350. https:\/\/doi.org\/10.1017\/S1041610222001041.","journal-title":"Int Psychogeriatr"},{"key":"1200_CR28","doi-asserted-by":"crossref","unstructured":"Guy W. ECDEU Assessment Manual for Psychopharmacology, Revised. Rockville: National Institute of Mental Health; 1976.","DOI":"10.1037\/e591322011-001"},{"key":"1200_CR29","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","volume":"212","author":"GM Simpson","year":"1970","unstructured":"Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970;212:11\u20139. https:\/\/doi.org\/10.1111\/j.1600-0447.1970.tb02066.x.","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"1200_CR30","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1192\/bjp.154.5.672","volume":"154","author":"TRE Barnes","year":"1989","unstructured":"Barnes TRE. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154:672\u20136. https:\/\/doi.org\/10.1192\/bjp.154.5.672.","journal-title":"Br J Psychiatry"},{"issue":"1","key":"1200_CR31","first-page":"26","volume":"6","author":"V Coric","year":"2009","unstructured":"Coric V, Stock EG, Pultz J, Marcus R, Sheehan DV. Sheehan Suicidality Tracking Scale (Sheehan-STS): preliminary results from a multicenter clinical trial in generalized anxiety disorder. Psychiatry (Edgmont). 2009;6(1):26\u201331.","journal-title":"Psychiatry (Edgmont)"},{"issue":"10","key":"1200_CR32","doi-asserted-by":"publisher","first-page":"4679","DOI":"10.1007\/s10072-024-07576-8","volume":"45","author":"G Marinheiro","year":"2024","unstructured":"Marinheiro G, Dantas JM, Mutarelli A, de Menegaz AA, Monteiro GA, Zerlotto DS, et al. Efficacy and safety of brexpiprazole for the treatment of agitation in Alzheimer\u2019s disease: a meta-analysis of randomized controlled trials. Neurol Sci. 2024;45(10):4679\u201386. https:\/\/doi.org\/10.1007\/s10072-024-07576-8.","journal-title":"Neurol Sci"},{"issue":"1","key":"1200_CR33","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12874-021-01228-7","volume":"21","author":"JA Watt","year":"2021","unstructured":"Watt JA, Veroniki AA, Tricco AC, Straus SE. Using a distribution-based approach and systematic review methods to derive minimum clinically important differences. BMC Med Res Methodol. 2021;21(1):41. https:\/\/doi.org\/10.1186\/s12874-021-01228-7.","journal-title":"BMC Med Res Methodol"},{"issue":"3","key":"1200_CR34","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1080\/14740338.2020.1713091","volume":"19","author":"BB Barton","year":"2020","unstructured":"Barton BB, Segger F, Fischer K, Obermeier M, Musil R. Update on weight-gain caused by antipsychotics: a systematic review and meta-analysis. Expert Opin Drug Saf. 2020;19(3):295\u2013314. https:\/\/doi.org\/10.1080\/14740338.2020.1713091.","journal-title":"Expert Opin Drug Saf"},{"issue":"1","key":"1200_CR35","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1017\/s1041610213001658","volume":"26","author":"AR Atti","year":"2014","unstructured":"Atti AR, Ferrari Gozzi B, Zuliani G, Bernabei V, Scudellari P, Berardi D, et al. A systematic review of metabolic side effects related to the use of antipsychotic drugs in dementia. Int Psychogeriatr. 2014;26(1):19\u201337. https:\/\/doi.org\/10.1017\/s1041610213001658.","journal-title":"Int Psychogeriatr"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01200-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-025-01200-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01200-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T14:01:37Z","timestamp":1757512897000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-025-01200-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,19]]},"references-count":35,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["1200"],"URL":"https:\/\/doi.org\/10.1007\/s40263-025-01200-9","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,19]]},"assertion":[{"value":"5 June 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was supported by Otsuka Pharmaceutical Development & Commercialization Inc. (Princeton, NJ, USA) and H. Lundbeck A\/S (Valby, Denmark). The sponsors were involved in the design of the research, the analysis and interpretation of data, and the writing and reviewing of this article. The sponsors paid the open access fee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Alpesh Shah, Dalei Chen, Denise Chang, Mary Slomkowski, Mary Hobart, and Malaak Brubaker are full-time employees of Otsuka Pharmaceutical Development & Commercialization Inc. Alvin Estilo, Daniel Lee, and Saloni Behl were full-time employees of Otsuka Pharmaceutical Development & Commercialization Inc. at the time of this work. Pamela L. Sheridan was a full-time employee of Lundbeck LLC at the time of this work. Uwa Kalu is a full-time employee of Lundbeck LLC. Nanco Hefting and Pedro Such are full-time employees of H. Lundbeck A\/S. George T Grossberg has received consulting fees from Acadia, Abbott, Axsome, Biogen, BMS, BioXcel, Eisai, Karuna, Lundbeck, MapLight Therapeutics, Otsuka, and Takeda. George T. Grossberg is on the Editorial Board for CNS Drugs, Journal of the American Medical Directors Association, and International Journal of Alzheimer\u2019s Disease; he was not involved in the selection of peer reviewers for this manuscript nor any of the subsequent editorial decisions. He is on Safety Monitoring Committees for Anavex, Quince, Merck, Newron, and Oligomerix.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"To submit inquiries related to Otsuka clinical research, or to request access to individual participant data (IPD) associated with any Otsuka clinical trial, please visit . For all approved IPD access requests, Otsuka will share anonymized IPD on a remotely accessible data sharing platform.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"This analysis used pooled data from published clinical trials. The trials were approved by relevant institutional review boards and independent ethics committees and were performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"This analysis used pooled data from published clinical trials. All participants and\/or their legal representatives provided written or electronic informed consent prior to the start of the trials.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors contributed to the study conception and design. Data analysis was performed by Dalei Chen and Denise Chang. All authors critically reviewed the manuscript for intellectual content. All authors read and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}